<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Medical therapy of hypercortisolism (Cushing's syndrome)</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Medical therapy of hypercortisolism (Cushing's syndrome)</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Medical therapy of hypercortisolism (Cushing's syndrome)</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Lynnette K Nieman, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">André Lacroix, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Katya Rubinow, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Aug 29, 2022.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>The hypercortisolism of Cushing's syndrome is primarily treated surgically, regardless of its cause (ie, due to corticotropin [ACTH]-producing pituitary tumor [Cushing's disease], ectopic ACTH secretion by a nonpituitary tumor, or cortisol secretion by an adrenal adenoma or carcinoma). However, when surgery is delayed, contraindicated, or unsuccessful, medical therapy is often required. Adrenal enzyme inhibitors are the most commonly used drugs, but adrenolytic agents, drugs that target a pituitary or ectopic tumor, and glucocorticoid-receptor antagonists are also available.</p><p>The pharmacologic management of hypercortisolemia in Cushing's syndrome will be reviewed here. An overview of the treatment options for Cushing's syndrome and additional details about drugs that inhibit cortisol synthesis are discussed separately. (See  <a class="medical medical_review" href="/d/html/174.html" rel="external">"Overview of the treatment of Cushing syndrome"</a> and  <a class="medical medical_review" href="/d/html/16322.html" rel="external">"Persistent or recurrent Cushing disease: Surgical adrenalectomy"</a>.)</p><p class="headingAnchor" id="H2"><span class="h1">INDICATIONS</span><span class="headingEndMark"> — </span>The main indications for medical therapy of Cushing's syndrome include (see  <a class="medical medical_review" href="/d/html/174.html" rel="external">"Overview of the treatment of Cushing syndrome"</a>):</p><p class="bulletIndent1"><span class="glyph">●</span>Control of hypercortisolism in preparation for surgery – Although the hypercortisolism of Cushing's disease is optimally treated surgically, medical therapy is often required when surgery is delayed. (See  <a class="medical medical_review" href="/d/html/174.html" rel="external">"Overview of the treatment of Cushing syndrome", section on 'Transsphenoidal surgery'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Management of hypercortisolism if surgery is contraindicated. (See  <a class="medical medical_review" href="/d/html/174.html" rel="external">"Overview of the treatment of Cushing syndrome", section on 'Medical therapy'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Management of persistent or recurrent hypercortisolism after initial surgery. (See  <a class="medical medical_review" href="/d/html/118.html" rel="external">"Primary therapy of Cushing disease: Transsphenoidal surgery and pituitary irradiation", section on 'Treatment if surgery fails'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Patients who have undergone radiation therapy – Control of hypercortisolism while waiting for the effect of pituitary radiation in patients with corticotropin (ACTH)-secreting pituitary tumors (Cushing's disease).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Patients with ectopic ACTH syndrome – Treatment of occult or metastatic ectopic ACTH syndrome.</p><p></p><p>Our approach is largely consistent with the Endocrine Society Clinical Practice Guideline [<a href="#rid1">1</a>].</p><p class="headingAnchor" id="H1340119271"><span class="h1">CHOOSING THERAPIES</span><span class="headingEndMark"> — </span>Medical treatment of Cushing's syndrome can be divided into two broad categories: medications that decrease cortisol production and those that antagonize the action of cortisol at the glucocorticoid receptor.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Drugs that decrease cortisol production</strong> – Drugs that decrease cortisol production include steroidogenesis inhibitors, which act directly on the adrenal gland to inhibit enzymes involved in cortisol synthesis and may also be adrenolytic, and agents that reduce corticotropin (ACTH) secretion by pituitary corticotroph tumors or ectopic tumors, and hence reduce the adrenal stimulation for cortisol production. (See <a class="local">'Adrenal enzyme inhibitors'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Glucocorticoid receptor antagonists</strong> – An example of a glucocorticoid receptor antagonist is <a class="drug drug_general" data-topicid="10263" href="/d/drug information/10263.html" rel="external">mifepristone</a>. (See <a class="local">'Glucocorticoid-receptor antagonists'</a> below.)</p><p></p><p class="headingAnchor" id="H2684156208"><span class="h2">Issues for all patients</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Patients' goals and preferences</strong> – These should be explored together before choosing medical therapy. For example, a young woman's desire for pregnancy in the near future may influence a choice of adrenalectomy over medical treatment. Other potential issues include a preference for oral versus injectable route of administration; daily versus multiple daily doses; impaired memory (ie, possible reduced adherence); a desire to "get on with life," which may favor surgery or agents with a faster onset of action; insurance, availability, and affordability.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>The variability in day-to-day cortisol production</strong> – In patients with highly variable cortisol production, fixed dosing regimens may result in adrenal insufficiency alternating with normal or increased cortisol production. Instead, a "block and replace" strategy is used in which the medication dose is titrated to completely block cortisol secretion, with the addition of a physiologic exogenous glucocorticoid dose to "replace" cortisol.</p><p></p><p class="bulletIndent1">Thus, before deciding on a specific medication, 24-hour urine cortisol secretion should be measured to determine the degree of variability of cortisol production. While no studies have identified criteria for "high" variability, one approach is to look at the percentage or fold changes in at least three pretreatment urinary free cortisol (UFC) values. If the pretreatment values differ by threefold, ideal dosing would achieve values of 20 to 60 mcg/day (within and slightly above the normal range of approximately 5 to 50 mcg/day). However, a result of 20 mcg/day implies threefold results of 0 to 60, risking adrenal insufficiency, and a value of 50 would imply possible results of 17 to 150 mcg/day, risking undertreatment. Thus, a variability criterion of no more than twofold is probably best to use when choosing a fixed-dose regimen.</p><p></p><p class="headingAnchor" id="H3567507027"><span class="h2">Considerations for individual medications</span><span class="headingEndMark"> — </span>These issues are discussed below:</p><p class="bulletIndent1"><span class="glyph">●</span>The cause of Cushing's syndrome – Some agents are used only for pituitary Cushing's or ectopic ACTH-producing tumors.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Likelihood of long-term normalization of signs and symptoms – Some agents are more effective when hypercortisolism is mild. Others may effectively mitigate hypercortisolism but have an adverse side-effect profile that prevents their use or limits long-term use.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The likelihood of adrenal insufficiency.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Drug-drug interactions.</p><p></p><p class="headingAnchor" id="H18"><span class="h1">INITIAL THERAPY</span></p><p class="headingAnchor" id="H3997055008"><span class="h2">Adrenal enzyme inhibitors</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="8589" href="/d/drug information/8589.html" rel="external">Ketoconazole</a>, <a class="drug drug_general" data-topicid="10156" href="/d/drug information/10156.html" rel="external">metyrapone</a>, and <a class="drug drug_general" data-topicid="9659" href="/d/drug information/9659.html" rel="external">mitotane</a> are orally active medications that inhibit one or more steps in cortisol synthesis  (<a class="graphic graphic_figure graphicRef114448" href="/d/graphic/114448.html" rel="external">figure 1</a>). They are most often used to control corticotropin (ACTH)-dependent cortisol excess [<a href="#rid2">2-6</a>]. These drugs are not available in all countries. The most commonly used agent is ketoconazole in the United States and metyrapone in the United Kingdom. Other drugs that inhibit adrenal enzymes but are either no longer available (aminoglutethimide and trilostane), or rarely used (<a class="drug drug_general" data-topicid="8450" href="/d/drug information/8450.html" rel="external">fluconazole</a>), will not be considered further. These drugs usually do not cause adrenal insufficiency in patients with normal hypothalamic-pituitary-adrenal function [<a href="#rid7">7</a>] but can do so in those with limited pituitary or adrenal reserve. (See <a class="local">'Replacement glucocorticoid therapy'</a> below.)</p><p>In addition to inhibiting adrenal enzymes, <a class="drug drug_general" data-topicid="9659" href="/d/drug information/9659.html" rel="external">mitotane</a> is adrenolytic and is used for the treatment of adrenocortical carcinoma (see  <a class="medical medical_review" href="/d/html/165.html" rel="external">"Treatment of adrenocortical carcinoma"</a>). The steroidogenesis inhibitor <a class="drug drug_general" data-topicid="8428" href="/d/drug information/8428.html" rel="external">etomidate</a> is the only agent for intravenous use.</p><p class="headingAnchor" id="H16432801"><span class="h3">Ketoconazole</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="8589" href="/d/drug information/8589.html" rel="external">Ketoconazole</a> is a racemic mixture of L-form and S-form enantiomers that inhibits the first step in cortisol biosynthesis (side-chain cleavage) and, to a lesser extent, the conversion of 11-deoxycortisol to cortisol; it is an even more potent inhibitor of C17-20 desmolase, decreasing androstenedione, testosterone, and estradiol production  (<a class="graphic graphic_figure graphicRef114448" href="/d/graphic/114448.html" rel="external">figure 1</a>). At therapeutic doses, it also impairs corticotroph adenylate cyclase activation and ACTH secretion in vitro [<a href="#rid8">8</a>]. However, the contribution of this effect to its action in patients with Cushing's disease has not been demonstrated.</p><p>In a series of 200 patients with Cushing's disease, 75 percent achieved either normal free cortisol (UFC) levels (49 percent) or at least a 50 percent decrease, at a median final dose of 600 mg/day. However, 20 percent stopped the treatment due to poor tolerance [<a href="#rid9">9</a>].</p><p><a class="drug drug_general" data-topicid="8589" href="/d/drug information/8589.html" rel="external">Ketoconazole</a> may cause reversible hepatotoxicity [<a href="#rid9">9,10</a>]. In the study described above [<a href="#rid9">9</a>], mild (&lt;5-fold normal values) and major (&gt;5-fold normal values) increases in liver enzymes were observed in 13.5 and 2.5 percent of patients, respectively. In 2013, the US Food and Drug Administration (FDA) issued a warning about the risk of potentially fatal liver toxicity, even in patients without pre-existing hepatic disease [<a href="#rid11">11</a>], which was followed by a temporary withdrawal in European countries. The regulatory warnings were revised to discourage use of ketoconazole for management of fungal infections, and the drug is now widely available [<a href="#rid12">12</a>]. In the United States, it is an off-label use for the treatment of Cushing's syndrome.</p><p class="bulletIndent1"><span class="glyph">●</span>Liver function tests should be performed before initiation of <a class="drug drug_general" data-topicid="8589" href="/d/drug information/8589.html" rel="external">ketoconazole</a>. The drug is contraindicated in patients with liver disease whose alanine aminotransferase (ALT) values are ≥3 times the upper normal range. Patients with elevated values &lt;3 times the upper normal range often have cortisol-induced nonalcoholic hepatosteatosis that improves with ketoconazole treatment.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>ALT should be monitored weekly for the first month, monthly for three months, and less frequently thereafter.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>If ALT values increase to ≥3 times the upper normal range, we suggest stopping the <a class="drug drug_general" data-topicid="8589" href="/d/drug information/8589.html" rel="external">ketoconazole</a> or reducing it to a previously well-tolerated dose.</p><p></p><p>Ketoconazole-induced decreases in estradiol and testosterone production may lead to gynecomastia, decreased libido, and impotence in men but usually are not clinically apparent in women because of the oligomenorrhea or amenorrhea associated with Cushing's syndrome [<a href="#rid13">13</a>].</p><p><a class="drug drug_general" data-topicid="8589" href="/d/drug information/8589.html" rel="external">Ketoconazole</a> is teratogenic and toxic to animal embryos but has been used successfully and without harm to fetuses from as early as the seventh week of pregnancy [<a href="#rid14">14,15</a>]. However, ketoconazole is not the treatment of choice during pregnancy. (See  <a class="medical medical_review" href="/d/html/139.html" rel="external">"Diagnosis and management of Cushing syndrome during pregnancy", section on 'Management'</a>.)</p><p><a class="drug drug_general" data-topicid="8589" href="/d/drug information/8589.html" rel="external">Ketoconazole</a> requires an acidic environment for maximal absorption; its bioavailability may be reduced as much as 50 percent if it is given with a proton pump inhibitor [<a href="#rid16">16</a>]. Such agents should be discontinued, if at all possible, if ketoconazole is used.</p><p><a class="drug drug_general" data-topicid="8589" href="/d/drug information/8589.html" rel="external">Ketoconazole</a> is a strong inhibitor of CYP3A4. Coadministration of CYP3A4 substrates should be avoided if possible and may result in increased plasma concentrations of these drugs, with increased or prolonged therapeutic or adverse effects. For example, coadministration of certain ergot derivatives, <a class="drug drug_general" data-topicid="9575" href="/d/drug information/9575.html" rel="external">lovastatin</a>, and <a class="drug drug_general" data-topicid="8453" href="/d/drug information/8453.html" rel="external">alprazolam</a> may result in dangerous elevations of those agents and is contraindicated [<a href="#rid17">17</a>].</p><p><a class="drug drug_general" data-topicid="8589" href="/d/drug information/8589.html" rel="external">Ketoconazole</a> can prolong the QT interval; thus concomitant administration of other agents that also prolong the QT interval (such as <a class="drug drug_general" data-topicid="9269" href="/d/drug information/9269.html" rel="external">cisapride</a>, <a class="drug drug_general" data-topicid="9623" href="/d/drug information/9623.html" rel="external">methadone</a>, <a class="drug drug_general" data-topicid="9846" href="/d/drug information/9846.html" rel="external">quinidine</a>) is contraindicated as they may synergize to cause life-threatening ventricular arrhythmia [<a href="#rid17">17</a>].</p><p class="headingAnchor" id="H1863083950"><span class="h3">Levoketoconazole</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="134730" href="/d/drug information/134730.html" rel="external">Levoketoconazole</a>, comprised of the pure L-form enantiomer of <a class="drug drug_general" data-topicid="8589" href="/d/drug information/8589.html" rel="external">ketoconazole</a>, inhibits adrenal steroidogenesis via inhibition of CYP3A4 with two to four times the potency of ketoconazole [<a href="#rid18">18,19</a>]. It is approved by the FDA for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome when surgery is not an option or when it has not been curative. </p><p>Clinical trials have demonstrated normalization of 24-hour urinary free cortisol levels in 49 percent (19 of 39) of subjects with initial values of two to five times the upper limit of normal [<a href="#rid20">20</a>]; however, only 31 percent (29 of 94) of the entire group had this response, as patients with higher initial UFC were less likely to respond. Patients also had improvement in quality of life, depression, and other signs of Cushing's syndrome [<a href="#rid21">21,22</a>]. Adverse events included increased ALT in 39 patients (greater than three times the upper limit of normal in 10), dose-related QT interval prolongation in five, and adrenal insufficiency in three.</p><p>As there has been no head-to-head comparison to <a class="drug drug_general" data-topicid="8589" href="/d/drug information/8589.html" rel="external">ketoconazole</a>, it is not clear whether <a class="drug drug_general" data-topicid="134730" href="/d/drug information/134730.html" rel="external">levoketoconazole</a> offers an advantage in terms of reduction of hepatic toxicity. However, it appears that the two agents have similar efficacy when urine free cortisol is elevated up to five-fold normal. Levoketoconazole has a longer half-life that allows for twice-daily administration; this is a potential advantage for patients who may be unable to adhere to the six- to eight-hour dosing interval for ketoconazole and <a class="drug drug_general" data-topicid="10156" href="/d/drug information/10156.html" rel="external">metyrapone</a>.</p><p class="headingAnchor" id="H16432822"><span class="h3">Metyrapone</span><span class="headingEndMark"> — </span>We do not suggest <a class="drug drug_general" data-topicid="10156" href="/d/drug information/10156.html" rel="external">metyrapone</a> as the first-line drug for women with Cushing's disease requiring long-term control of hypercortisolism. However, its use is not precluded in women for projected short-term use (for example, for treatment before surgery), or when <a class="drug drug_general" data-topicid="8589" href="/d/drug information/8589.html" rel="external">ketoconazole</a> is not a good alternative.</p><p><a class="drug drug_general" data-topicid="10156" href="/d/drug information/10156.html" rel="external">Metyrapone</a> inhibits CYP11B1, leading to increases in 11-deoxycortisol, the immediate precursor of cortisol. It also inhibits CYP11B2, leading to increases in deoxycorticosterone, the immediate precursor of aldosterone  (<a class="graphic graphic_figure graphicRef56413" href="/d/graphic/56413.html" rel="external">figure 2</a>), which may cause salt retention and hypertension. As a consequence of decreasing cortisol levels, ACTH secretion from a pituitary tumor may increase, stimulating increases in adrenal androgen production, which can cause hirsutism in women.</p><p>When given in a dose of approximately 4 g/day, <a class="drug drug_general" data-topicid="10156" href="/d/drug information/10156.html" rel="external">metyrapone</a> decreases cortisol secretion, but usually not to normal, in patients with Cushing's disease [<a href="#rid23">23</a>]. Thus, like the other adrenal enzyme inhibitors, metyrapone is most useful as adjunctive therapy in patients with mild disease or after pituitary irradiation, which prevents a further increase in ACTH secretion [<a href="#rid2">2,24-27</a>]. A dose of 500 to 750 mg three or four times a day is usually required in these patients. Metyrapone has been used in pregnancy with mixed results efficacy [<a href="#rid28">28-30</a>]. (See  <a class="medical medical_review" href="/d/html/139.html" rel="external">"Diagnosis and management of Cushing syndrome during pregnancy", section on 'Management'</a>.)</p><p>In the largest retrospective, multicenter series, 195 patients with Cushing's syndrome (all causes) were treated with <a class="drug drug_general" data-topicid="10156" href="/d/drug information/10156.html" rel="external">metyrapone</a> (as monotherapy in 84 percent) [<a href="#rid31">31</a>]. Complete normalization of cortisol secretion was achieved in approximately 50 percent of patients treated both short and long term. Among 38 patients treated long term (mean 18 months), 77 percent achieved complete normalization of cortisol secretion. The drug was generally well tolerated: gastrointestinal upset (23 percent) and hypoadrenalism (7 percent) were the most frequent side effects; hypokalemia, hypertension, and hirsutism were very seldom found.</p><p><a class="drug drug_general" data-topicid="10156" href="/d/drug information/10156.html" rel="external">Metyrapone</a> is currently available in North America through its distributor HRA Pharma (Paris, France) via its specialty pharmacy Direct Success Inc with order forms available on the web (www.metopirone.us) or by phone at 1-855-674-7663. Like <a class="drug drug_general" data-topicid="8589" href="/d/drug information/8589.html" rel="external">ketoconazole</a>, its use for treatment of Cushing's syndrome is an off-label use.</p><p class="headingAnchor" id="H4072361100"><span class="h3">Osilodrostat</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="127397" href="/d/drug information/127397.html" rel="external">Osilodrostat</a> is an oral agent that has been approved for adults with Cushing's disease who are not candidates for pituitary surgery or who have undergone transsphenoidal surgery but have persistent disease [<a href="#rid32">32-34</a>]. Like <a class="drug drug_general" data-topicid="10156" href="/d/drug information/10156.html" rel="external">metyrapone</a>, it blocks the 11-beta-hydroxylase enzymes (CYP11B1 and CYP11B2), thereby reducing the synthesis of aldosterone and cortisol [<a href="#rid32">32</a>]. Osilodrostat's safety and effectiveness for treating adults with Cushing's disease was evaluated in a six-month, single-arm, open-label study of 137 adult patients with Cushing's disease, who were either not surgical candidates or who had undergone transsphenoidal surgery but were not cured. The starting dose for all was 2 mg twice daily that could be increased by 1 to 2 mg every two weeks up to 30 mg twice/day. At the end of 24 weeks, approximately one-half of patients had 24-hour UFC levels less than or equal to the upper limit of normal (ULN) [<a href="#rid35">35</a>].</p><p>In this same trial, subjects who achieved a 24-hour UFC less than or equal to ULN at week 24, without up-titration after week 12, entered into an 8-week randomized trial of continued <a class="drug drug_general" data-topicid="127397" href="/d/drug information/127397.html" rel="external">osilodrostat</a> or placebo [<a href="#rid36">36</a>]. Of the 137 patients initially enrolled, 72 were eligible for the randomized trial. More patients maintained a complete response with osilodrostat than placebo (86 versus 29 percent, respectively).</p><p>Side effects of the drug include hypocortisolism, prolongation of the QT interval, nausea, headache, and adrenal insufficiency [<a href="#rid33">33,36,37</a>]. There are limited data on a faster dose escalation strategy or use of the agent in patients without Cushing's disease. In one report of three patients with ectopic ACTH secretion, the dose was increased by 1 mg every two to five days, based on morning plasma cortisol levels [<a href="#rid38">38</a>].</p><p class="headingAnchor" id="H6330785"><span class="h3">Mitotane</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="9659" href="/d/drug information/9659.html" rel="external">Mitotane</a> is an adrenolytic drug that acts on adrenocortical cell mitochondria to inhibit CYP11B1 (11-beta-hydroxylase) and cholesterol side-chain cleavage (CYP11A1) enzymes. A metabolite binds to important macromolecules in the mitochondria, causing mitochondrial destruction and necrosis of adrenocortical cells [<a href="#rid39">39</a>]. Because of its adrenolytic action, it is used primarily for the treatment of adrenal carcinoma, which will not be considered further here. (See  <a class="medical medical_review" href="/d/html/165.html" rel="external">"Treatment of adrenocortical carcinoma", section on 'Adjuvant mitotane'</a> and <a class="local">'Replacement glucocorticoid therapy'</a> below.)</p><p><a class="drug drug_general" data-topicid="9659" href="/d/drug information/9659.html" rel="external">Mitotane</a> also can be used to achieve medical adrenalectomy with or without pituitary irradiation in patients with Cushing's disease or as an adjunctive medication in patients with ectopic ACTH secretion [<a href="#rid40">40-42</a>]. Mitotane treatment of Cushing's syndrome not caused by adrenocortical cancer should be started with 0.5 g given at bedtime, adding single 0.5 g doses at a mealtime every week or so, as the patient's tolerance permits, to reach a maximal dose of 2 to 3 g/day, one-half of which is taken at bedtime to reduce nausea. Thereafter, the concentrations are maintained by doses of 1 to 2 g daily. At these doses, mitotane tends to spare the zona glomerulosa [<a href="#rid43">43</a>] so that mineralocorticoid replacement is not needed.</p><p>The major side effects are nausea, vomiting, and anorexia. Additional side effects that occur with the higher doses used for adrenal carcinoma are discussed separately. (See  <a class="medical medical_review" href="/d/html/165.html" rel="external">"Treatment of adrenocortical carcinoma", section on 'Adjuvant mitotane'</a>.)</p><p>When given as adjunctive therapy after radiotherapy for Cushing's disease, <a class="drug drug_general" data-topicid="9659" href="/d/drug information/9659.html" rel="external">mitotane</a> is stopped when cortisol levels normalize, on average after six to nine months. A sustained cure rate was reported in approximately 60 percent of cases at 5 to 15 years [<a href="#rid40">40</a>]. Similar findings were reported in a study of 46 patients treated with higher doses of mitotane but no pituitary irradiation [<a href="#rid41">41</a>]. Four of 92 patients developed Nelson syndrome.</p><p><a class="drug drug_general" data-topicid="9659" href="/d/drug information/9659.html" rel="external">Mitotane</a> is taken up by adipose tissues and persists in plasma long after the drug is discontinued [<a href="#rid44">44</a>]. Mitotane is teratogenic and should not be given to pregnant women; women anticipating pregnancy should have levels measured after its discontinuation to ensure that it is safe to proceed [<a href="#rid45">45</a>].</p><p class="headingAnchor" id="H1447968773"><span class="h2">Dose adjustments and monitoring</span><span class="headingEndMark"> — </span>Unless <a class="drug drug_general" data-topicid="9659" href="/d/drug information/9659.html" rel="external">mitotane</a> is given in adrenolytic doses, these medications do not permanently cure the hypercortisolism, leading to recurrence when the drug is discontinued. As a result, they must be continued indefinitely until bilateral adrenalectomy is performed, or a tumor is found and excised or pituitary radiotherapy is effective.</p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="8589" href="/d/drug information/8589.html" rel="external">Ketoconazole</a><strong>/</strong><a class="drug drug_general" data-topicid="10156" href="/d/drug information/10156.html" rel="external">metyrapone</a><strong>/</strong><a class="drug drug_general" data-topicid="127397" href="/d/drug information/127397.html" rel="external">osilodrostat</a> – Doses of ketoconazole and metyrapone can be increased every three to seven days based on serum cortisol and/or urine cortisol excretion. In clinical trials, the osilodrostat dose was adjusted every two weeks; this dose adjustment period is recommended in the FDA label. At the outset of treatment with these steroidogenesis inhibitors, we recommend measurement of a morning serum cortisol level on the day that urine is returned for cortisol measurement. This allows the two to be correlated, allowing later use of the morning cortisol only, as most patients find a blood draw to be more convenient than urine collection.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>For patients with relatively invariant cortisol production, a fixed dose schedule can be used with the goal of "normalization" of cortisol. A serum cortisol target of 7 to 12 mcg/dL (193 to 331 nmol/L) can be used while awaiting the urine result, with a goal urine value in the middle to slightly above the upper limit of the reference range. While this approach minimizes the chance of adrenal insufficiency, patients nevertheless should receive education about adrenal insufficiency signs and symptoms and how to administer emergency doses of glucocorticoid. (See  <a class="medical medical_review" href="/d/html/155.html" rel="external">"Treatment of adrenal insufficiency in adults"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>For patients requiring a "block and replace" strategy, the dose of drug(s) is increased at intervals until serum or urine cortisol is in the normal range, at which time a glucocorticoid is added. The dose is increased further until serum or urine cortisol values are very low or undetectable. (See <a class="local">'Replacement glucocorticoid therapy'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Once the dose appears to be optimal, monitoring may occur less often, perhaps monthly or less frequently.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="10156" href="/d/drug information/10156.html" rel="external">Metyrapone</a> administration increases 11-deoxycortisol, which may cross-react with the antibodies in some cortisol immunoassays, while tandem mass spectrometry results are not affected [<a href="#rid46">46</a>]. If urine or serum cortisol measurement by tandem mass spectrometry is not available, a cortisol immunoassay that does not cross-react with 11-deoxycortisol should be used.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="9659" href="/d/drug information/9659.html" rel="external">Mitotane</a> – Doses of mitotane are increased more slowly, due to its long half-life. Urinary cortisol excretion is the optimal measure of the efficacy of mitotane therapy. Mitotane increases cortisol-binding globulin (CBG) levels, so that serum cortisol levels increase and do not reliably reflect biologically active free levels [<a href="#rid47">47</a>]. If serum cortisol levels are used to monitor treatment, they should be correlated with urinary cortisol excretion, at least initially and after dose changes.</p><p></p><p class="headingAnchor" id="H2738359950"><span class="h2">Replacement glucocorticoid therapy</span><span class="headingEndMark"> — </span>In a block and replace strategy, patients must receive replacement glucocorticoid therapy when the serum or urine cortisol is in the normal range.</p><p class="bulletIndent1"><span class="glyph">●</span>When <a class="drug drug_general" data-topicid="8589" href="/d/drug information/8589.html" rel="external">ketoconazole</a>, <a class="drug drug_general" data-topicid="127397" href="/d/drug information/127397.html" rel="external">osilodrostat</a>, and/or <a class="drug drug_general" data-topicid="10156" href="/d/drug information/10156.html" rel="external">metyrapone</a> are used to decrease cortisol levels, any glucocorticoid replacement can be used in the usual way (see  <a class="medical medical_review" href="/d/html/155.html" rel="external">"Treatment of adrenal insufficiency in adults"</a>). If <a class="drug drug_general" data-topicid="8535" href="/d/drug information/8535.html" rel="external">hydrocortisone</a> is used, urine collections to assess efficacy must be done after switching to <a class="drug drug_general" data-topicid="9334" href="/d/drug information/9334.html" rel="external">dexamethasone</a>, which does not cross-react in cortisol assays. Alternatively, a pre-hydrocortisone serum cortisol level can be used to monitor therapeutic effectiveness, with a goal of very low or undetectable level of urine or serum cortisol.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>When <a class="drug drug_general" data-topicid="9659" href="/d/drug information/9659.html" rel="external">mitotane</a> is used, one cannot predict when a patient will become hypocortisolemic. As a result, replacement glucocorticoid, usually 5 mg of <a class="drug drug_general" data-topicid="9809" href="/d/drug information/9809.html" rel="external">prednisone</a> or 0.5 mg of <a class="drug drug_general" data-topicid="9334" href="/d/drug information/9334.html" rel="external">dexamethasone</a> each day, should be started when cortisol in urine or saliva begin to decrease. Mitotane increases the metabolism of dexamethasone [<a href="#rid48">48</a>], <a class="drug drug_general" data-topicid="8455" href="/d/drug information/8455.html" rel="external">fludrocortisone</a>, and cortisol and induces an increase in CBG levels [<a href="#rid5">5</a>]. Thus, replacement dose <a class="drug drug_general" data-topicid="8535" href="/d/drug information/8535.html" rel="external">hydrocortisone</a> usually requires a two- to threefold increase in the usual dose after long-term therapy with mitotane. (See  <a class="medical medical_review" href="/d/html/165.html" rel="external">"Treatment of adrenocortical carcinoma", section on 'Adjuvant mitotane'</a>.)</p><p></p><p class="bulletIndent1">If <a class="drug drug_general" data-topicid="9334" href="/d/drug information/9334.html" rel="external">dexamethasone</a> is used for replacement therapy during <a class="drug drug_general" data-topicid="9659" href="/d/drug information/9659.html" rel="external">mitotane</a> administration, it may be necessary to increase its dose (and that of <a class="drug drug_general" data-topicid="8455" href="/d/drug information/8455.html" rel="external">fludrocortisone</a>, if it is required) to three to seven times the usual dose; in these cases, amelioration of symptoms of hypocortisolism or normalization of UFC values must be used to guide glucocorticoid replacement, while symptoms and signs of volume depletion or excess (postural hypotension, systemic hypertension, or edema), serum electrolytes, and plasma renin activity are used to guide mineralocorticoid replacement. (See  <a class="medical medical_review" href="/d/html/155.html" rel="external">"Treatment of adrenal insufficiency in adults"</a>.)</p><p></p><p class="bulletIndent1">Because <a class="drug drug_general" data-topicid="9659" href="/d/drug information/9659.html" rel="external">mitotane</a> levels may remain measurable for months after its discontinuation due to release from adipose tissue, cortisol levels may remain suppressed so that replacement glucocorticoid may have to be tapered over a period of several weeks to months.</p><p></p><p class="headingAnchor" id="H92978950"><span class="h2">Combination therapy</span><span class="headingEndMark"> — </span>Combinations of these drugs often have additive or synergistic therapeutic effects at lower individual doses, thereby minimizing side effects.</p><p class="bulletIndent1"><span class="glyph">●</span>If <a class="drug drug_general" data-topicid="8589" href="/d/drug information/8589.html" rel="external">ketoconazole</a> does not control cortisol secretion, it should be maintained at a total dose of 1200 mg/day and <a class="drug drug_general" data-topicid="10156" href="/d/drug information/10156.html" rel="external">metyrapone</a> and/or <a class="drug drug_general" data-topicid="9659" href="/d/drug information/9659.html" rel="external">mitotane</a> should be added.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>We suggest adding <a class="drug drug_general" data-topicid="10156" href="/d/drug information/10156.html" rel="external">metyrapone</a> at a dose of 250 mg two or three times a day and increasing rapidly, to a maximum dose of approximately 4.5 g/day [<a href="#rid16">16</a>]. Most patients show near-maximal responses at a daily dose of 2 g (see <a class="local">'Metyrapone'</a> above). Particularly in patients with severe hypercortisolism, it is important to control cortisol synthesis quickly. In these patients, the doses should be increased every two or three days if laboratory results are available.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>An alternative approach is to begin treatment with <a class="drug drug_general" data-topicid="10156" href="/d/drug information/10156.html" rel="external">metyrapone</a> and add <a class="drug drug_general" data-topicid="8589" href="/d/drug information/8589.html" rel="external">ketoconazole</a> if cortisol is not adequately controlled.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In one study of 11 cases of severe hypercortisolism in whom adrenalectomy was not feasible, triple drug therapy with <a class="drug drug_general" data-topicid="9659" href="/d/drug information/9659.html" rel="external">mitotane</a>, <a class="drug drug_general" data-topicid="10156" href="/d/drug information/10156.html" rel="external">metyrapone</a>, and <a class="drug drug_general" data-topicid="8589" href="/d/drug information/8589.html" rel="external">ketoconazole</a> normalized UFC [<a href="#rid49">49</a>].</p><p></p><p class="headingAnchor" id="H3587011867"><span class="h2">Intravenous etomidate</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="8428" href="/d/drug information/8428.html" rel="external">Etomidate</a> is a substituted imidazole anesthetic drug that blocks CYP11B1 synthesis of cortisol and is the only available agent for hospitalized patients unable to take medication by mouth  (<a class="graphic graphic_figure graphicRef71558" href="/d/graphic/71558.html" rel="external">figure 3</a>). Etomidate is infused intravenously, initially with a low, nonhypnotic dose of 0.04 to 0.05 mg/kg per hour (approximately 2.5 to 3 mg/hour), with dose titration based upon serum cortisol (up to 0.1 to 0.3 mg/kg/hour). This approach has been effective in approximately 30 adults and children who were acutely ill [<a href="#rid50">50</a>]. In a study of a standardized protocol in seven patients with severe hypercortisolism, etomidate was given with an optional 5 mg intravenous bolus and an infusion dose of 0.02 mg/kg/hour. Infusion rates were adjusted in increments of 0.01 to 0.02 mg/kg/hour based upon serum cortisol measurements every six hours; rapid control of hypercortisolemia was achieved in all patients [<a href="#rid51">51</a>].</p><p>Monitoring in an intensive care unit is suggested when using <a class="drug drug_general" data-topicid="8428" href="/d/drug information/8428.html" rel="external">etomidate</a>. Intravenous <a class="drug drug_general" data-topicid="8535" href="/d/drug information/8535.html" rel="external">hydrocortisone</a> is added if complete block rather than cortisol normalization is the goal. Sedation, a theoretical side effect of this drug, was not observed in the few patients studied to date.</p><p class="headingAnchor" id="H22"><span class="h1">OTHER AGENTS</span></p><p class="headingAnchor" id="H6331226"><span class="h2">Drugs that target a pituitary tumor</span><span class="headingEndMark"> — </span>Only the somatostatin analogue, <a class="drug drug_general" data-topicid="87457" href="/d/drug information/87457.html" rel="external">pasireotide</a>, and the dopamine agonist, <a class="drug drug_general" data-topicid="8600" href="/d/drug information/8600.html" rel="external">cabergoline</a>, have shown benefit; other agents that are not effective include <a class="drug drug_general" data-topicid="9164" href="/d/drug information/9164.html" rel="external">bromocriptine</a>, <a class="drug drug_general" data-topicid="9311" href="/d/drug information/9311.html" rel="external">cyproheptadine</a>, and <a class="drug drug_general" data-topicid="10035" href="/d/drug information/10035.html" rel="external">valproate</a>.</p><p class="headingAnchor" id="H458568781"><span class="h3">Cabergoline</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="8600" href="/d/drug information/8600.html" rel="external">Cabergoline</a> is useful when Cushing's disease is associated with urinary free cortisol (UFC) values up to twice normal. In two studies, chronic cabergoline therapy (1 mg once weekly to 1 mg orally every day) decreased 24-hour UFC to ≤125 percent of normal in 12 of 42 patients with Cushing's disease [<a href="#rid52">52,53</a>]. Normalization of UFC was achieved in 30 percent of patients with up to five years of follow-up [<a href="#rid53">53</a>]. A meta-analysis found that patients with milder hypercortisolism were more likely to respond [<a href="#rid54">54</a>]. Gastrointestinal side effects, particularly nausea (14 percent) and dizziness were most common; severe adverse effects included adrenal insufficiency and hypotension. The agent has been used in a small number of pregnant women with good outcomes [<a href="#rid55">55</a>].</p><p class="headingAnchor" id="H458568732"><span class="h3">Pasireotide</span><span class="headingEndMark"> — </span>The somatostatin analog <a class="drug drug_general" data-topicid="87457" href="/d/drug information/87457.html" rel="external">pasireotide</a> binds to somatostatin receptors and blocks the release of corticotropin (ACTH) from the corticotrophs via its high affinity for somatostatin receptor subtype 5 [<a href="#rid56">56</a>]. Pasireotide injection has been approved in the United States, Europe, Canada, and parts of Asia and South America and is recommended for the treatment of patients with Cushing's disease for whom surgery has been unsuccessful or who are not surgical candidates [<a href="#rid1">1,57</a>]. It is available as a short-acting subcutaneous preparation for twice-daily use and as a once-monthly intramuscular (IM) injection. In a study of 162 patients with Cushing's disease receiving subcutaneous pasireotide (0.6 or 0.9 mg twice daily for six months), 24-hour UFC decreased by a mean of 48 percent in the whole group and normalized it in 21 of 80 (26 percent) and 12 of 82 (15 percent) of those in the 0.9 or 0.6 mg group, respectively [<a href="#rid58">58</a>]. Patients who achieved UFC control also experienced other clinical improvements, including a decrease in total and low-density lipoprotein cholesterol [<a href="#rid59">59</a>]. Reductions in blood pressure and body mass index occurred even without normalization of UFC. Hyperglycemia was common, occurring in 118 of 162 patients (73 percent); 74 of 162 patients (63 percent) required initiation of a glucose-lowering medication. Pasireotide-associated hyperglycemia is related to decreases in insulin secretion and incretin hormone responses (glucagon-like peptide 1 [GLP-1] and glucose-dependent insulinotropic polypeptide [GIP]), but not to changes in hepatic/peripheral insulin sensitivity [<a href="#rid60">60</a>]. Other side effects were similar to other somatostatin analogs (gastrointestinal symptoms and gallstones). (See  <a class="medical medical_review" href="/d/html/6625.html" rel="external">"Treatment of acromegaly"</a>.)</p><p>The recommended initial dose of the short-acting formulation is 0.6 mg subcutaneously twice daily, which may be increased to 0.9 mg twice daily if UFC does not normalize after one to two months of therapy. If there is no clinical response to 0.9 mg, treatment should either be stopped or combined therapy should be considered. A sustained response for up to five years has been reported in three individuals [<a href="#rid61">61,62</a>]; two had initially developed glucose intolerance with <a class="drug drug_general" data-topicid="87457" href="/d/drug information/87457.html" rel="external">pasireotide</a>, but with clinical and biochemical reversal of their hypercortisolism, they were eventually able to discontinue all diabetes pharmacotherapy [<a href="#rid62">62</a>].</p><p>A long-term study of 53 patients showed a tumor volume reduction of at least 20 percent at 6 and 12 months that was more common in those taking the 0.9 mg dose than the 0.6 mg dose (75 and 89 percent versus 44 and 50 percent) [<a href="#rid63">63</a>].</p><p>In a trial of 150 patients receiving either 10 or 30 mg once-monthly IM <a class="drug drug_general" data-topicid="87457" href="/d/drug information/87457.html" rel="external">pasireotide</a> for 12 months, approximately 40 percent in each group reached the primary endpoint (UFC concentration less than or equal to upper limit of normal by seven months) [<a href="#rid64">64</a>]. Adverse events include hyperglycemia (47 to 49 percent), diarrhea (35 to 43 percent), gallstones (20 to 45 percent), and type 2 diabetes (19 to 24 percent). In an open-label extension study that enrolled 81 of the 150 patients, the safety profile was similar to that reported in the first 12 months [<a href="#rid65">65</a>]. The recommended starting dose for pasireotide is 10 mg.</p><p>The monthly preparation may be useful for patients who have difficulty remembering to take medications, but is not a first-line choice for patients with diabetes.</p><p>The <a class="drug drug_general" data-topicid="87457" href="/d/drug information/87457.html" rel="external">pasireotide</a> warning and precaution for hyperglycemia and diabetes has been updated to include ketoacidosis [<a href="#rid66">66</a>].</p><p class="headingAnchor" id="H368270665"><span class="h2">Drugs that target an ectopic ACTH-secreting tumor</span><span class="headingEndMark"> — </span>Chemotherapy or immunotherapy may reduce corticotropin (ACTH) and cortisol levels in patients with ectopic ACTH secretion [<a href="#rid67">67-69</a>]. A few patients have been successfully treated with <a class="drug drug_general" data-topicid="9714" href="/d/drug information/9714.html" rel="external">octreotide</a> and/or <a class="drug drug_general" data-topicid="8600" href="/d/drug information/8600.html" rel="external">cabergoline</a> [<a href="#rid70">70-72</a>]. However, these are case reports or small series, and the overall efficacy of these approaches is not known.</p><p class="headingAnchor" id="H458568952"><span class="h2">Combination therapy</span><span class="headingEndMark"> — </span>In a report of 17 patients with Cushing's disease, the somatostatin analog <a class="drug drug_general" data-topicid="87457" href="/d/drug information/87457.html" rel="external">pasireotide</a>, followed by <a class="drug drug_general" data-topicid="8600" href="/d/drug information/8600.html" rel="external">cabergoline</a>, and, if necessary, <a class="drug drug_general" data-topicid="8589" href="/d/drug information/8589.html" rel="external">ketoconazole</a>, achieved normalization in UFC in five (29 percent for pasireotide alone), four (53 percent for pasireotide and cabergoline), and six patients (88 percent for three drugs), respectively [<a href="#rid73">73</a>].</p><p>In another report, for patients in whom <a class="drug drug_general" data-topicid="8600" href="/d/drug information/8600.html" rel="external">cabergoline</a> therapy (3 mg/week) provided a suboptimal response, addition of <a class="drug drug_general" data-topicid="8589" href="/d/drug information/8589.html" rel="external">ketoconazole</a> (200 to 400 mg daily) achieved a normal UFC in six of nine patients [<a href="#rid52">52</a>].</p><p>In another study, <a class="drug drug_general" data-topicid="8600" href="/d/drug information/8600.html" rel="external">cabergoline</a> (n = 6, dose up to 3 mg weekly) or <a class="drug drug_general" data-topicid="8589" href="/d/drug information/8589.html" rel="external">ketoconazole</a> (n = 8, daily dose of 200 to 600 mg) was the first agent for four to six months [<a href="#rid74">74</a>]. UFC remained abnormal with the initial treatment but normalized in 13 patients on combination therapy.</p><p>The combination of <a class="drug drug_general" data-topicid="9659" href="/d/drug information/9659.html" rel="external">mitotane</a> (3 to 5 g/24 hours), <a class="drug drug_general" data-topicid="10156" href="/d/drug information/10156.html" rel="external">metyrapone</a> (3 to 4.5 g/24 hours), and <a class="drug drug_general" data-topicid="8589" href="/d/drug information/8589.html" rel="external">ketoconazole</a> (400 to 1200 mg/24 hours) was able to rapidly correct severe hypercortisolism in a series of 11 cases of Cushing's syndrome in acute care situations [<a href="#rid49">49</a>].</p><p class="headingAnchor" id="H6330490"><span class="h2">Glucocorticoid-receptor antagonists</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="10263" href="/d/drug information/10263.html" rel="external">Mifepristone</a> (RU-486) is an anti-progestational drug that is best known as an abortifacient. At much higher doses, it acts as a glucocorticoid receptor antagonist. Currently, mifepristone is the only available glucocorticoid antagonist, although other agents are in clinical trials.</p><p><a class="drug drug_general" data-topicid="10263" href="/d/drug information/10263.html" rel="external">Mifepristone</a> is approved in the United States as a once-daily oral medication to control hyperglycemia secondary to hypercortisolism in adults with endogenous Cushing's syndrome and type 2 diabetes or glucose intolerance who have failed surgery or are not candidates for surgery [<a href="#rid75">75</a>]. Because patients were not categorized as clinically normal during treatment, the role of mifepristone apart from treatment of hyperglycemia is not clear [<a href="#rid76">76</a>].</p><p><a class="drug drug_general" data-topicid="10263" href="/d/drug information/10263.html" rel="external">Mifepristone</a> may be a reasonable short-term intervention for patients with Cushing's syndrome who have an acute crisis, such as cortisol-induced psychosis, as symptoms improve rapidly in response to the glucocorticoid receptor blockade [<a href="#rid77">77,78</a>].</p><p><a class="drug drug_general" data-topicid="10263" href="/d/drug information/10263.html" rel="external">Mifepristone</a> also blocks the action of exogenous glucocorticoids, making it difficult to treat symptoms of adrenal insufficiency. Should symptoms of adrenal insufficiency occur, we suggest giving <a class="drug drug_general" data-topicid="9334" href="/d/drug information/9334.html" rel="external">dexamethasone</a> 4 mg to overcome the blockade.</p><p>Because <a class="drug drug_general" data-topicid="10263" href="/d/drug information/10263.html" rel="external">mifepristone</a> blocks cortisol action, the levels of ACTH and cortisol increase in patients with Cushing's disease [<a href="#rid79">79</a>] and are variable in patients with ectopic ACTH secretion [<a href="#rid80">80</a>], so that hormonal measurement cannot be used to judge either therapeutic efficacy or adrenal insufficiency. Instead, the goal is normalization of clinical and biochemical manifestations of hypercortisolism in each individual. For example, if hypertension, weight gain, and diabetes are signs/symptoms for a specific patient, monitoring should ensure that these improve and then resolve. It may be helpful to develop a list of each patient's signs and symptoms of Cushing's syndrome and then monitor these regularly, increasing the dose of the medication if they do not improve.</p><p class="headingAnchor" id="H763885081"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/d/html/112709.html" rel="external">"Society guideline links: Diagnosis and treatment of Cushing syndrome"</a>.)</p><p class="headingAnchor" id="H23"><span class="h1">INFORMATION FOR PATIENTS</span><span class="headingEndMark"> — </span>UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5<sup>th</sup> to 6<sup>th</sup> grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10<sup>th</sup> to 12<sup>th</sup> grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.</p><p>Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient info" and the keyword(s) of interest.)</p><p class="bulletIndent1"><span class="glyph">●</span>Basics topics (see  <a class="medical medical_basics" href="/d/html/15600.html" rel="external">"Patient education: Cushing syndrome (The Basics)"</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Beyond the Basics topics (see  <a class="medical medical_patient" href="/d/html/2173.html" rel="external">"Patient education: Cushing syndrome (Beyond the Basics)"</a> and  <a class="medical medical_patient" href="/d/html/2177.html" rel="external">"Patient education: Cushing syndrome treatment (Beyond the Basics)"</a>)</p><p></p><p class="headingAnchor" id="H601222861"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span>The hypercortisolism in Cushing's syndrome is primarily treated surgically, regardless of its cause. However, when surgery is delayed, contraindicated, or unsuccessful, medical therapy is often required. (See <a class="local">'Indications'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The main indications for pharmacologic control of hypercortisolism include: in preparation for surgery, persistence or recurrence of hypercortisolism after surgery, while waiting for the effect of pituitary radiation, occult ectopic corticotropin (ACTH) syndrome, severe or malignancy-related hypercortisolism, and when surgery is contraindicated. (See <a class="local">'Indications'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Among patients with hypercortisolism in whom medical therapy is indicated, we suggest <a class="drug drug_general" data-topicid="8589" href="/d/drug information/8589.html" rel="external">ketoconazole</a> as initial therapy (<a class="grade" href="https://medilib.ir/uptodate/show/grade_6" rel="external">Grade 2C</a>). Liver function tests must be carefully monitored because of rare occurrences of hepatotoxicity (see <a class="local">'Ketoconazole'</a> above). If ketoconazole does not control cortisol secretion, we suggest adding <a class="drug drug_general" data-topicid="10156" href="/d/drug information/10156.html" rel="external">metyrapone</a> (<a class="grade" href="https://medilib.ir/uptodate/show/grade_6" rel="external">Grade 2C</a>). (See <a class="local">'Initial therapy'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>An alternative approach is to start with <a class="drug drug_general" data-topicid="10156" href="/d/drug information/10156.html" rel="external">metyrapone</a> and add <a class="drug drug_general" data-topicid="8589" href="/d/drug information/8589.html" rel="external">ketoconazole</a> if cortisol secretion is not controlled. (See <a class="local">'Issues for all patients'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="9659" href="/d/drug information/9659.html" rel="external">Mitotane</a> is an adrenocorticolytic drug that is used primarily for the treatment of adrenal carcinoma. (See <a class="local">'Mitotane'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="9659" href="/d/drug information/9659.html" rel="external">Mitotane</a> also can be used to as adjunctive therapy during or after pituitary irradiation in patients with Cushing's disease. The usual duration of mitotane therapy in patients with Cushing's disease is six to nine months. (See <a class="local">'Mitotane'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="9659" href="/d/drug information/9659.html" rel="external">Mitotane</a> has significant side effects. However, important advantages over surgical adrenalectomy include a possible decreased risk of developing Nelson syndrome and the possibility of not requiring mineralocorticoid replacement. (See <a class="local">'Mitotane'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Drugs directed at reducing ACTH levels in Cushing's disease include the dopamine agonist, <a class="drug drug_general" data-topicid="8600" href="/d/drug information/8600.html" rel="external">cabergoline</a> (off-label use), and the parenteral somatostatin analog <a class="drug drug_general" data-topicid="87457" href="/d/drug information/87457.html" rel="external">pasireotide</a> (approved for therapy of Cushing's disease). (See <a class="local">'Cabergoline'</a> above and <a class="local">'Pasireotide'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="10263" href="/d/drug information/10263.html" rel="external">Mifepristone</a>, a glucocorticoid-receptor antagonist, is approved in the United States for treatment of hyperglycemia in Cushing's syndrome patients who cannot undergo surgery. (See <a class="local">'Other agents'</a> above.)</p><p></p><p class="headingAnchor" id="H1846823269"><span class="h1">DISCLOSURE</span><span class="headingEndMark"> — </span>The views expressed in this topic are those of the author(s) and do not reflect the official views or policy of the United States Government or its components.</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Nieman LK, Biller BM, Findling JW, et al. Treatment of Cushing's Syndrome: An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab 2015; 100:2807.</a></li><li><a class="nounderline abstract_t">Jeffcoate WJ, Rees LH, Tomlin S, et al. Metyrapone in long-term management of Cushing's disease. Br Med J 1977; 2:215.</a></li><li><a class="nounderline abstract_t">Komanicky P, Spark RF, Melby JC. Treatment of Cushing's syndrome with trilostane (WIN 24,540), an inhibitor of adrenal steroid biosynthesis. J Clin Endocrinol Metab 1978; 47:1042.</a></li><li><a class="nounderline abstract_t">Loli P, Berselli ME, Tagliaferri M. Use of ketoconazole in the treatment of Cushing's syndrome. J Clin Endocrinol Metab 1986; 63:1365.</a></li><li><a class="nounderline abstract_t">Schulte HM, Benker G, Reinwein D, et al. Infusion of low dose etomidate: correction of hypercortisolemia in patients with Cushing's syndrome and dose-response relationship in normal subjects. J Clin Endocrinol Metab 1990; 70:1426.</a></li><li><a class="nounderline abstract_t">Riedl M, Maier C, Zettinig G, et al. Long term control of hypercortisolism with fluconazole: case report and in vitro studies. Eur J Endocrinol 2006; 154:519.</a></li><li><a class="nounderline abstract_t">LIDDLE GW, ISLAND D, LANCE EM, HARRIS AP. Alterations of adrenal steroid patterns in man resulting from treatment with a chemical inhibitor of 11 beta-hydroxylation. J Clin Endocrinol Metab 1958; 18:906.</a></li><li><a class="nounderline abstract_t">Stalla GK, Stalla J, Huber M, et al. Ketoconazole inhibits corticotropic cell function in vitro. Endocrinology 1988; 122:618.</a></li><li><a class="nounderline abstract_t">Castinetti F, Guignat L, Giraud P, et al. Ketoconazole in Cushing's disease: is it worth a try? J Clin Endocrinol Metab 2014; 99:1623.</a></li><li><a class="nounderline abstract_t">McCance DR, Hadden DR, Kennedy L, et al. Clinical experience with ketoconazole as a therapy for patients with Cushing's syndrome. Clin Endocrinol (Oxf) 1987; 27:593.</a></li><li class="breakAll">Drug Safety Communication: FDA limits usage of Nizoral (ketoconazole) oral tablets due to potentially fatal liver injury and risk of drug interactions and adrenal gland problems. August 26, 2013. http://www.fda.gov/Drugs/DrugSafety/ucm362415.htm http://www.fda.gov/Drugs/DrugSafety/ucm362415.htm (Accessed on October 21, 2013).</li><li class="breakAll">Recommendation for maintenance of orphan designation at the time of marketing authorization: Ketoconazole HRA (ketoconazole) for the treatment of Cushing’s syndrome. European Medicines Agency/Committee for Orphan Medicinal Products orphan designation recommendation. Last updated January 30, 2015. European Medicines Agency. (Available online at www.ema.europa.eu/docs/en_GB/document_library/Orphan_review/2015/01/WC500181644.pdf (accessed September 28, 2015)).</li><li><a class="nounderline abstract_t">Gal M, Orly J, Barr I, et al. Low dose ketoconazole attenuates serum androgen levels in patients with polycystic ovary syndrome and inhibits ovarian steroidogenesis in vitro. Fertil Steril 1994; 61:823.</a></li><li><a class="nounderline abstract_t">Amado JA, Pesquera C, Gonzalez EM, et al. Successful treatment with ketoconazole of Cushing's syndrome in pregnancy. Postgrad Med J 1990; 66:221.</a></li><li><a class="nounderline abstract_t">Berwaerts J, Verhelst J, Mahler C, Abs R. Cushing's syndrome in pregnancy treated by ketoconazole: case report and review of the literature. Gynecol Endocrinol 1999; 13:175.</a></li><li><a class="nounderline abstract_t">Ogawa R, Echizen H. Drug-drug interaction profiles of proton pump inhibitors. Clin Pharmacokinet 2010; 49:509.</a></li><li class="breakAll">https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/018533s041lbl.pdf (Accessed on August 18, 2020).</li><li><a class="nounderline abstract_t">Creemers SG, Feelders RA, de Jong FH, et al. Levoketoconazole, the 2S,4R Enantiomer of Ketoconazole, a New Steroidogenesis Inhibitor for Cushing's Syndrome Treatment. J Clin Endocrinol Metab 2021; 106:e1618.</a></li><li><a class="nounderline abstract_t">Dilmaghanian S, Gerber JG, Filler SG, et al. Enantioselectivity of inhibition of cytochrome P450 3A4 (CYP3A4) by ketoconazole: Testosterone and methadone as substrates. Chirality 2004; 16:79.</a></li><li><a class="nounderline abstract_t">Castinetti F, Nieman LK, Reincke M, Newell-Price J. Approach to the Patient Treated with Steroidogenesis Inhibitors. J Clin Endocrinol Metab 2021; 106:2114.</a></li><li><a class="nounderline abstract_t">Pivonello R, Elenkova A, Fleseriu M, et al. Levoketoconazole in the Treatment of Patients With Cushing's Syndrome and Diabetes Mellitus: Results From the SONICS Phase 3 Study. Front Endocrinol (Lausanne) 2021; 12:595894.</a></li><li><a class="nounderline abstract_t">Geer EB, Salvatori R, Elenkova A, et al. Levoketoconazole improves clinical signs and symptoms and patient-reported outcomes in patients with Cushing's syndrome. Pituitary 2021; 24:104.</a></li><li><a class="nounderline abstract_t">Santen RJ, Wells SA, Runić S, et al. Adrenal suppression with aminoglutethimide. I. Differential e-fects of aminoglutethimide on glucocorticoid metabolism as a rationale for use of hydrocortisone. J Clin Endocrinol Metab 1977; 45:469.</a></li><li><a class="nounderline abstract_t">Orth DN, Liddle GW. Results of treatment in 108 patients with Cushing's syndrome. N Engl J Med 1971; 285:243.</a></li><li><a class="nounderline abstract_t">Child DF, Burke CW, Burley DM, et al. Drug controlled of Cushing's syndrome. Combined aminoglutethimide and metyrapone therapy. Acta Endocrinol (Copenh) 1976; 82:330.</a></li><li><a class="nounderline abstract_t">Verhelst JA, Trainer PJ, Howlett TA, et al. Short and long-term responses to metyrapone in the medical management of 91 patients with Cushing's syndrome. Clin Endocrinol (Oxf) 1991; 35:169.</a></li><li><a class="nounderline abstract_t">Orth DN. Metyrapone is useful only as adjunctive therapy in Cushing's disease. Ann Intern Med 1978; 89:128.</a></li><li><a class="nounderline abstract_t">Aron DC, Schnall AM, Sheeler LR. Cushing's syndrome and pregnancy. Am J Obstet Gynecol 1990; 162:244.</a></li><li><a class="nounderline abstract_t">Buescher MA, McClamrock HD, Adashi EY. Cushing syndrome in pregnancy. Obstet Gynecol 1992; 79:130.</a></li><li><a class="nounderline abstract_t">Lindsay JR, Nieman LK. The hypothalamic-pituitary-adrenal axis in pregnancy: challenges in disease detection and treatment. Endocr Rev 2005; 26:775.</a></li><li><a class="nounderline abstract_t">Daniel E, Aylwin S, Mustafa O, et al. Effectiveness of Metyrapone in Treating Cushing's Syndrome: A Retrospective Multicenter Study in 195 Patients. J Clin Endocrinol Metab 2015; 100:4146.</a></li><li><a class="nounderline abstract_t">Feelders RA, Newell-Price J, Pivonello R, et al. Advances in the medical treatment of Cushing's syndrome. Lancet Diabetes Endocrinol 2019; 7:300.</a></li><li><a class="nounderline abstract_t">Duggan S. Osilodrostat: First Approval. Drugs 2020; 80:495.</a></li><li><a class="nounderline abstract_t">Osilodrostat (Isturisa) for Cushing's disease. Med Lett Drugs Ther 2021; 63:21.</a></li><li><a class="nounderline abstract_t">Fleseriu M, Pivonello R, Young J, et al. Osilodrostat, a potent oral 11β-hydroxylase inhibitor: 22-week, prospective, Phase II study in Cushing's disease. Pituitary 2016; 19:138.</a></li><li><a class="nounderline abstract_t">Pivonello R, Fleseriu M, Newell-Price J, et al. Efficacy and safety of osilodrostat in patients with Cushing's disease (LINC 3): a multicentre phase III study with a double-blind, randomised withdrawal phase. Lancet Diabetes Endocrinol 2020; 8:748.</a></li><li><a class="nounderline abstract_t">Broersen LHA, Jha M, Biermasz NR, et al. Effectiveness of medical treatment for Cushing's syndrome: a systematic review and meta-analysis. Pituitary 2018; 21:631.</a></li><li><a class="nounderline abstract_t">Haissaguerre M, Puerto M, Nunes ML, Tabarin A. Efficacy and tolerance of osilodrostat in patients with severe Cushing's syndrome due to non-pituitary cancers. Eur J Endocrinol 2020; 183:L7.</a></li><li><a class="nounderline abstract_t">Poli G, Guasti D, Rapizzi E, et al. Morphofunctional effects of mitotane on mitochondria in human adrenocortical cancer cells. Endocr Relat Cancer 2013; 20:537.</a></li><li><a class="nounderline abstract_t">Schteingart DE, Tsao HS, Taylor CI, et al. Sustained remission of Cushing's disease with mitotane and pituitary irradiation. Ann Intern Med 1980; 92:613.</a></li><li><a class="nounderline abstract_t">Luton JP, Mahoudeau JA, Bouchard P, et al. Treatment of Cushing's disease by O,p'DDD. Survey of 62 cases. N Engl J Med 1979; 300:459.</a></li><li><a class="nounderline abstract_t">Baudry C, Coste J, Bou Khalil R, et al. Efficiency and tolerance of mitotane in Cushing's disease in 76 patients from a single center. Eur J Endocrinol 2012; 167:473.</a></li><li><a class="nounderline abstract_t">VILAR O, TULLNER WW. Effects of o,p' DDD on histology and 17-hydroxycorticosteroid output of the dog adrenal cortex. Endocrinology 1959; 65:80.</a></li><li><a class="nounderline abstract_t">Hogan TF, Citrin DL, Johnson BM, et al. o,p'-DDD (mitotane) therapy of adrenal cortical carcinoma: observations on drug dosage, toxicity, and steroid replacement. Cancer 1978; 42:2177.</a></li><li><a class="nounderline abstract_t">Leiba S, Weinstein R, Shindel B, et al. The protracted effect of o,p'-DDD in Cushing's disease and its impact on adrenal morphogenesis of young human embryo. Ann Endocrinol (Paris) 1989; 50:49.</a></li><li><a class="nounderline abstract_t">Monaghan PJ, Owen LJ, Trainer PJ, et al. Comparison of serum cortisol measurement by immunoassay and liquid chromatography-tandem mass spectrometry in patients receiving the 11β-hydroxylase inhibitor metyrapone. Ann Clin Biochem 2011; 48:441.</a></li><li><a class="nounderline abstract_t">Nader N, Raverot G, Emptoz-Bonneton A, et al. Mitotane has an estrogenic effect on sex hormone-binding globulin and corticosteroid-binding globulin in humans. J Clin Endocrinol Metab 2006; 91:2165.</a></li><li><a class="nounderline abstract_t">Robinson BG, Hales IB, Henniker AJ, et al. The effect of o,p'-DDD on adrenal steroid replacement therapy requirements. Clin Endocrinol (Oxf) 1987; 27:437.</a></li><li><a class="nounderline abstract_t">Kamenický P, Droumaguet C, Salenave S, et al. Mitotane, metyrapone, and ketoconazole combination therapy as an alternative to rescue adrenalectomy for severe ACTH-dependent Cushing's syndrome. J Clin Endocrinol Metab 2011; 96:2796.</a></li><li><a class="nounderline abstract_t">Preda VA, Sen J, Karavitaki N, Grossman AB. Etomidate in the management of hypercortisolaemia in Cushing's syndrome: a review. Eur J Endocrinol 2012; 167:137.</a></li><li><a class="nounderline abstract_t">Carroll TB, Peppard WJ, Herrmann DJ, et al. Continuous Etomidate Infusion for the Management of Severe Cushing Syndrome: Validation of a Standard Protocol. J Endocr Soc 2019; 3:1.</a></li><li><a class="nounderline abstract_t">Vilar L, Naves LA, Azevedo MF, et al. Effectiveness of cabergoline in monotherapy and combined with ketoconazole in the management of Cushing's disease. Pituitary 2010; 13:123.</a></li><li><a class="nounderline abstract_t">Godbout A, Manavela M, Danilowicz K, et al. Cabergoline monotherapy in the long-term treatment of Cushing's disease. Eur J Endocrinol 2010; 163:709.</a></li><li><a class="nounderline abstract_t">Palui R, Sahoo J, Kamalanathan S, et al. Effect of cabergoline monotherapy in Cushing's disease: an individual participant data meta-analysis. J Endocrinol Invest 2018; 41:1445.</a></li><li><a class="nounderline abstract_t">Sek KS, Deepak DS, Lee KO. Use of cabergoline for the management of persistent Cushing's disease in pregnancy. BMJ Case Rep 2017; 2017.</a></li><li><a class="nounderline abstract_t">Hofland LJ, van der Hoek J, Feelders R, et al. The multi-ligand somatostatin analogue SOM230 inhibits ACTH secretion by cultured human corticotroph adenomas via somatostatin receptor type 5. Eur J Endocrinol 2005; 152:645.</a></li><li class="breakAll">European Medicines Agency. Summary of product characteristics: Signifor 0.3 mg solution for injection. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/002052/WC500128056.pdf (Accessed on December 21, 2012).</li><li><a class="nounderline abstract_t">Colao A, Petersenn S, Newell-Price J, et al. A 12-month phase 3 study of pasireotide in Cushing's disease. N Engl J Med 2012; 366:914.</a></li><li><a class="nounderline abstract_t">Pivonello R, Petersenn S, Newell-Price J, et al. Pasireotide treatment significantly improves clinical signs and symptoms in patients with Cushing's disease: results from a Phase III study. Clin Endocrinol (Oxf) 2014; 81:408.</a></li><li><a class="nounderline abstract_t">Henry RR, Ciaraldi TP, Armstrong D, et al. Hyperglycemia associated with pasireotide: results from a mechanistic study in healthy volunteers. J Clin Endocrinol Metab 2013; 98:3446.</a></li><li><a class="nounderline abstract_t">Libé R, Groussin L, Bertherat J. Pasireotide in Cushing's disease. N Engl J Med 2012; 366:2134; author reply 2134.</a></li><li><a class="nounderline abstract_t">MacKenzie Feder J, Bourdeau I, Vallette S, et al. Pasireotide monotherapy in Cushing's disease: a single-centre experience with 5-year extension of phase III Trial. Pituitary 2014; 17:519.</a></li><li><a class="nounderline abstract_t">Lacroix A, Gu F, Schopohl J, et al. Pasireotide treatment significantly reduces tumor volume in patients with Cushing's disease: results from a Phase 3 study. Pituitary 2020; 23:203.</a></li><li><a class="nounderline abstract_t">Lacroix A, Gu F, Gallardo W, et al. Efficacy and safety of once-monthly pasireotide in Cushing's disease: a 12 month clinical trial. Lancet Diabetes Endocrinol 2018; 6:17.</a></li><li><a class="nounderline abstract_t">Fleseriu M, Petersenn S, Biller BMK, et al. Long-term efficacy and safety of once-monthly pasireotide in Cushing's disease: A Phase III extension study. Clin Endocrinol (Oxf) 2019; 91:776.</a></li><li class="breakAll">https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/203255s008lbl.pdf (Accessed on July 31, 2020).</li><li><a class="nounderline abstract_t">Takahashi T, Hatao K, Yamashita Y, Tanizawa Y. Ectopic ACTH syndrome due to thymic atypical carcinoid treated with combination chemotherapy of cisplatin and etoposide. Intern Med 2003; 42:1197.</a></li><li><a class="nounderline abstract_t">Yoshino K, Takeda N, Morita H, et al. Marked increase in plasma ACTH with tumor reduction after chemotherapy in ectopic ACTH syndrome. Endocr J 1999; 46:331.</a></li><li><a class="nounderline abstract_t">Barroso-Sousa R, Lerario AM, Evangelista J, et al. Complete resolution of hypercortisolism with sorafenib in a patient with advanced medullary thyroid carcinoma and ectopic ACTH (adrenocorticotropic hormone) syndrome. Thyroid 2014; 24:1062.</a></li><li><a class="nounderline abstract_t">Modica R, Colao A, Faggiano A. Complete clinical and biochemical control with cabergoline and octreotide in a patient with ectopic ACTH syndrome before surgery. J Endocrinol Invest 2015; 38:373.</a></li><li><a class="nounderline abstract_t">Bruno OD, Danilowicz K, Manavela M, et al. Long-term management with octreotide or cabergoline in ectopic corticotropin hypersecretion: case report and literature review. Endocr Pract 2010; 16:829.</a></li><li><a class="nounderline abstract_t">Pivonello R, Ferone D, Lamberts SW, Colao A. Cabergoline plus lanreotide for ectopic Cushing's syndrome. N Engl J Med 2005; 352:2457.</a></li><li><a class="nounderline abstract_t">Feelders RA, de Bruin C, Pereira AM, et al. Pasireotide alone or with cabergoline and ketoconazole in Cushing's disease. N Engl J Med 2010; 362:1846.</a></li><li><a class="nounderline abstract_t">Barbot M, Albiger N, Ceccato F, et al. Combination therapy for Cushing's disease: effectiveness of two schedules of treatment: should we start with cabergoline or ketoconazole? Pituitary 2014; 17:109.</a></li><li class="breakAll">Corcept Therapeutics Incorporated Announces FDA Approval of Korlym™ (mifepristone) 300 mg Tablets: First and Only Approved Medication for Cushing’s Syndrome Patients - February 17, 2012 http://www.corcept.com/news_events/pr_1329524335 (Accessed on February 29, 2012).</li><li><a class="nounderline abstract_t">Mifepristone (Korlym) for Cushing's syndrome. Med Lett Drugs Ther 2012; 54:46.</a></li><li><a class="nounderline abstract_t">Castinetti F, Fassnacht M, Johanssen S, et al. Merits and pitfalls of mifepristone in Cushing's syndrome. Eur J Endocrinol 2009; 160:1003.</a></li><li><a class="nounderline abstract_t">Johanssen S, Allolio B. Mifepristone (RU 486) in Cushing's syndrome. Eur J Endocrinol 2007; 157:561.</a></li><li><a class="nounderline abstract_t">Fleseriu M, Biller BM, Findling JW, et al. Mifepristone, a glucocorticoid receptor antagonist, produces clinical and metabolic benefits in patients with Cushing's syndrome. J Clin Endocrinol Metab 2012; 97:2039.</a></li><li><a class="nounderline abstract_t">Wannachalee T, Turcu AF, Auchus RJ. Mifepristone in the treatment of the ectopic adrenocorticotropic hormone syndrome. Clin Endocrinol (Oxf) 2018; 89:570.</a></li></ol></div><div id="topicVersionRevision">Topic 119 Version 35.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26222757" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Treatment of Cushing's Syndrome: An Endocrine Society Clinical Practice Guideline.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/195666" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Metyrapone in long-term management of Cushing's disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/233687" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Treatment of Cushing's syndrome with trilostane (WIN 24,540), an inhibitor of adrenal steroid biosynthesis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3023421" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Use of ketoconazole in the treatment of Cushing's syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2159485" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Infusion of low dose etomidate: correction of hypercortisolemia in patients with Cushing's syndrome and dose-response relationship in normal subjects.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16556713" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Long term control of hypercortisolism with fluconazole: case report and in vitro studies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/13563620" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Alterations of adrenal steroid patterns in man resulting from treatment with a chemical inhibitor of 11 beta-hydroxylation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2448128" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Ketoconazole inhibits corticotropic cell function in vitro.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24471573" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Ketoconazole in Cushing's disease: is it worth a try?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3450457" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Clinical experience with ketoconazole as a therapy for patients with Cushing's syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3450457" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Clinical experience with ketoconazole as a therapy for patients with Cushing's syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3450457" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Clinical experience with ketoconazole as a therapy for patients with Cushing's syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8174717" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Low dose ketoconazole attenuates serum androgen levels in patients with polycystic ovary syndrome and inhibits ovarian steroidogenesis in vitro.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2362890" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Successful treatment with ketoconazole of Cushing's syndrome in pregnancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10451809" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Cushing's syndrome in pregnancy treated by ketoconazole: case report and review of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20608754" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Drug-drug interaction profiles of proton pump inhibitors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20608754" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Drug-drug interaction profiles of proton pump inhibitors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33399817" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Levoketoconazole, the 2S,4R Enantiomer of Ketoconazole, a New Steroidogenesis Inhibitor for Cushing's Syndrome Treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14712470" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Enantioselectivity of inhibition of cytochrome P450 3A4 (CYP3A4) by ketoconazole: Testosterone and methadone as substrates.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33675650" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Approach to the Patient Treated with Steroidogenesis Inhibitors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33897615" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Levoketoconazole in the Treatment of Patients With Cushing's Syndrome and Diabetes Mellitus: Results From the SONICS Phase 3 Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33216275" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Levoketoconazole improves clinical signs and symptoms and patient-reported outcomes in patients with Cushing's syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/198423" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Adrenal suppression with aminoglutethimide. I. Differential e-fects of aminoglutethimide on glucocorticoid metabolism as a rationale for use of hydrocortisone.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4326256" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Results of treatment in 108 patients with Cushing's syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/179256" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Drug controlled of Cushing's syndrome. Combined aminoglutethimide and metyrapone therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1657460" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Short and long-term responses to metyrapone in the medical management of 91 patients with Cushing's syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/208445" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Metyrapone is useful only as adjunctive therapy in Cushing's disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2405679" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Cushing's syndrome and pregnancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1727571" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Cushing syndrome in pregnancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15827110" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : The hypothalamic-pituitary-adrenal axis in pregnancy: challenges in disease detection and treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26353009" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Effectiveness of Metyrapone in Treating Cushing's Syndrome: A Retrospective Multicenter Study in 195 Patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30033041" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Advances in the medical treatment of Cushing's syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32141023" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Osilodrostat: First Approval.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Osilodrostat (Isturisa) for Cushing's disease</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26542280" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Osilodrostat, a potent oral 11β-hydroxylase inhibitor: 22-week, prospective, Phase II study in Cushing's disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32730798" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Efficacy and safety of osilodrostat in patients with Cushing's disease (LINC 3): a multicentre phase III study with a double-blind, randomised withdrawal phase.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29855779" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Effectiveness of medical treatment for Cushing's syndrome: a systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32688343" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Efficacy and tolerance of osilodrostat in patients with severe Cushing's syndrome due to non-pituitary cancers.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23722227" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Morphofunctional effects of mitotane on mitochondria in human adrenocortical cancer cells.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6247946" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Sustained remission of Cushing's disease with mitotane and pituitary irradiation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/215912" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Treatment of Cushing's disease by O,p'DDD. Survey of 62 cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22815335" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Efficiency and tolerance of mitotane in Cushing's disease in 76 patients from a single center.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/13663851" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Effects of o,p' DDD on histology and 17-hydroxycorticosteroid output of the dog adrenal cortex.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/719602" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : o,p'-DDD (mitotane) therapy of adrenal cortical carcinoma: observations on drug dosage, toxicity, and steroid replacement.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2729882" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : The protracted effect of o,p'-DDD in Cushing's disease and its impact on adrenal morphogenesis of young human embryo.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21813575" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Comparison of serum cortisol measurement by immunoassay and liquid chromatography-tandem mass spectrometry in patients receiving the 11β-hydroxylase inhibitor metyrapone.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16551731" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Mitotane has an estrogenic effect on sex hormone-binding globulin and corticosteroid-binding globulin in humans.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2830062" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : The effect of o,p'-DDD on adrenal steroid replacement therapy requirements.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21752886" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Mitotane, metyrapone, and ketoconazole combination therapy as an alternative to rescue adrenalectomy for severe ACTH-dependent Cushing's syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22577107" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Etomidate in the management of hypercortisolaemia in Cushing's syndrome: a review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30560224" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Continuous Etomidate Infusion for the Management of Severe Cushing Syndrome: Validation of a Standard Protocol.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19943118" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Effectiveness of cabergoline in monotherapy and combined with ketoconazole in the management of Cushing's disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20702648" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Cabergoline monotherapy in the long-term treatment of Cushing's disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30097903" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Effect of cabergoline monotherapy in Cushing's disease: an individual participant data meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28710189" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Use of cabergoline for the management of persistent Cushing's disease in pregnancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15817922" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : The multi-ligand somatostatin analogue SOM230 inhibits ACTH secretion by cultured human corticotroph adenomas via somatostatin receptor type 5.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15817922" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : The multi-ligand somatostatin analogue SOM230 inhibits ACTH secretion by cultured human corticotroph adenomas via somatostatin receptor type 5.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22397653" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : A 12-month phase 3 study of pasireotide in Cushing's disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24533697" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Pasireotide treatment significantly improves clinical signs and symptoms in patients with Cushing's disease: results from a Phase III study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23733372" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Hyperglycemia associated with pasireotide: results from a mechanistic study in healthy volunteers.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22646647" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Pasireotide in Cushing's disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24287689" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Pasireotide monotherapy in Cushing's disease: a single-centre experience with 5-year extension of phase III Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31875276" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Pasireotide treatment significantly reduces tumor volume in patients with Cushing's disease: results from a Phase 3 study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29032078" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Efficacy and safety of once-monthly pasireotide in Cushing's disease: a 12 month clinical trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31465533" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Long-term efficacy and safety of once-monthly pasireotide in Cushing's disease: A Phase III extension study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31465533" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Long-term efficacy and safety of once-monthly pasireotide in Cushing's disease: A Phase III extension study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14714958" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Ectopic ACTH syndrome due to thymic atypical carcinoid treated with combination chemotherapy of cisplatin and etoposide.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10460019" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Marked increase in plasma ACTH with tumor reduction after chemotherapy in ectopic ACTH syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24499195" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Complete resolution of hypercortisolism with sorafenib in a patient with advanced medullary thyroid carcinoma and ectopic ACTH (adrenocorticotropic hormone) syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25480427" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Complete clinical and biochemical control with cabergoline and octreotide in a patient with ectopic ACTH syndrome before surgery.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20497940" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : Long-term management with octreotide or cabergoline in ectopic corticotropin hypersecretion: case report and literature review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15944436" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : Cabergoline plus lanreotide for ectopic Cushing's syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20463350" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : Pasireotide alone or with cabergoline and ketoconazole in Cushing's disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23468128" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : Combination therapy for Cushing's disease: effectiveness of two schedules of treatment: should we start with cabergoline or ketoconazole?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23468128" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : Combination therapy for Cushing's disease: effectiveness of two schedules of treatment: should we start with cabergoline or ketoconazole?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22683927" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : Mifepristone (Korlym) for Cushing's syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19289534" id="rid76" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>77 : Merits and pitfalls of mifepristone in Cushing's syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17984235" id="rid77" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>78 : Mifepristone (RU 486) in Cushing's syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22466348" id="rid78" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>79 : Mifepristone, a glucocorticoid receptor antagonist, produces clinical and metabolic benefits in patients with Cushing's syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30019523" id="rid79" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>80 : Mifepristone in the treatment of the ectopic adrenocorticotropic hormone syndrome.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
